Muvalaplin

Muvalaplin is a trivalent binder of apolipoprotein A (ApoA). It selectively binds to ApoA kringle domain IV type 8 (KIV8) over KIV2 (IC50s = 22 and 3,900 nM, respectively). Muvalaplin also binds to rat plasminogen (Kd = 50 = 0.09 nM). Muvalaplin decreases plasma levels of lipoprotein A in mice expressing both human ApoA and human ApoB (LPA x ApoB100, ED50 = 3 mg/kg). It reduces plasma levels of lipoprotein A in cynomolgus monkeys when administered at a dose of 100 mg/kg per day. Muvalaplin (31.6 mg/kg for four days) decreases ex vivo plasmin activity and plasminogen levels after administration in rats.Formal Name: (alphaS,alpha'S,alpha''S,3R,3'R,3''R)-alpha,alpha',alpha''-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-3-pyrrolidineacetic acid. CAS Number: 2565656-70-2. Synonyms: LY3473329. Molecular Formula: C42H54N4O6. Formula Weight: 710.9. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: PBS (pH 7.2): Slightly Soluble: 0.1-1 mg/ml. SMILES: O=C(O)[C@H]([C@@]1([H])CNCC1)CC2=CC(CN(CC3=CC(C[C@@H]([C@@]4([H])CCNC4)C(O)=O)=CC=C3)CC5=CC(C[C@@H]([C@@]6([H])CCNC6)C(O)=O)=CC=C5)=CC=C2. InChi Code: InChI=1S/C42H54N4O6/c47-40(48)37(34-10-13-43-22-34)19-28-4-1-7-31(16-28)25-46(26-32-8-2-5-29(17-32)20-38(41(49)50)35-11-14-44-23-35)27-33-9-3-6-30(18-33)21-39(42(51)52)36-12-15-45-24-36/h1-9,16-18,34-39,43-45H,10-15,19-27H2,(H,47,48)(H,49,50)(H,51,52)/t34-,35-,36+,37-,38-,39-/m0/s1. InChi Key: BRLGERLDHZRETI-IFATVDFYSA-N.